Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Select coverage from IAS 2017 Conference is included below:

Novel PHIA Project Collecting HIV Biomarkers in Children
Jessica Justman, MD, shares how the PHIA project is collecting HIV biomarkers in children.
Long-Acting Injectable: An Exciting New Option for HIV Prevention
Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.
Challenges Faced When Creating a Vaccine for HIV
Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.
What Were the Results of the Phase 3 EMERALD Trial?
Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.
How Can Decision Makers Use the Population-based HIV Impact Assessment Project Data?
Jessica Justman, MD, explains how decision makers can use the Population-based HIV Impact Assessment Project data.
Does Cabotegravir Interact with Any Other Medications?
Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.
Latest Results of the Population-Based HIV Impact Assessment Project
Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).
Who is the Target Population for Cabotegravir?
Alex Rinehart, PhD, identifies the target population for cabotegravir.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.